Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

2 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 4

2(50.0%)

Phase 2

1(25.0%)

N/A

1(25.0%)

4Total

Phase 4(2)

Phase 2(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT07357584Phase 4Not Yet Recruiting

Efficacy and Safety of Doravirine in the Rapid Initiation

Role: collaborator

NCT06951399Phase 2Not Yet Recruiting

Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer

Role: collaborator

NCT06588257Phase 4Active Not Recruiting

Acceptability of the HPV Vaccine and Anal HPV in Transgender Women and Men Who Have Sex With Men: A Pilot Study

Role: collaborator

NCT06995157Not ApplicableRecruiting

Characteristics of Human Papillomavirus (HPV) Infections and HPV Vaccine Attitudes Among Slovenian Women After the Introduction of HPV Vaccination

Role: collaborator

NCT06700941Completed

Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological Assessment

Role: collaborator

NCT06675721Not Yet Recruiting

A Survey of Acceptance and Factors Associated With Hesitancy Vaccination in Northeast Brazil

Role: collaborator

NCT03557853Completed

Clinical and Radiological Manifestations of Coxitis in Patients With Ankylosing Spondylitis Treated With Golimumab

Role: lead

NCT04253119Completed

ART First-line Treatment Durability in Russia

Role: lead

NCT05721092Completed

Assessment of Knowledge on Pneumococcal Vaccination Among Diabetologists in India

Role: collaborator

NCT05322083Unknown

HIV A6 Genome In ART Unsuccessful Patients On DOR

Role: collaborator

All 10 trials loaded